CLNN
Clene Inc.·Healthcare
6.11
3.628%(−0.23)
Market ClosedLast Updated: — ET
52W L: $2.2852W H: $13.50
CLNN NEWS
globenewswire.com
Mar 12
Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026 O versubscribed registered direct offering of over $28 million priced above market Initial financing tranche of over $6 million, which will provide cash runway to the end of the third quarter enabling funding through potential NDA acceptance decision by the FDA Completion of this financing through its three tranches is expected to provide the Company with sufficient capital into 2027 SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its full year 2025 financial results and provided recent updates on its CNM-Au8 programs. “Our next key milestone is the upcoming Type C face-to-face meeting with the U.S. Food and Drug Administration (FDA) on Clene's biomarker and survival data, which if positive, will facilitate filing of an new drug application (NDA) under an accelerated approval pathway for ALS by the end of the second quarter of 2026,” said Rob Etherington, President and CEO of Clene.
globenewswire.com
Feb 24
Clene Issues Stockholder Letter Highlighting Upcoming CNM-Au8® 2026 Catalysts
SALT LAKE CITY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today issued a letter to stockholders outlining key anticipated regulatory and clinical milestones for CNM-Au8® in 2026.
defenseworld.net
Feb 22
Contrasting Ventyx Biosciences (NASDAQ:VTYX) & Clene (NASDAQ:CLNN)
Ventyx Biosciences (NASDAQ: VTYX - Get Free Report) and Clene (NASDAQ: CLNN - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings. Analyst Recommendations This is a breakdown of recent
defenseworld.net
Feb 20
Clene Inc. (NASDAQ:CLNN) Receives $32.60 Consensus Target Price from Analysts
Clene Inc. (NASDAQ: CLNN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price target among
globenewswire.com
Feb 19
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.
defenseworld.net
Jan 26
Brokerages Set Clene Inc. (NASDAQ:CLNN) PT at $32.60
Shares of Clene Inc. (NASDAQ: CLNN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year price target
